AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Antibacterial Agents Against Methicilin- and Vancomycin-Resistant Bacteria

Summary: Researchers at Purdue University have identified compounds with potent antibacterial activities. The most potent compounds inhibited growth of various-resistant Gram-positive bacterial pathogens. Some compounds were active against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (VISA and VRSA respectively), and vancomycin-resistant Enterococcus faecalis (VRE). Through resistance generation experiments it was revealed that MRSA could not develop resistance to one of these compounds.

Technology Benefits: Compounds can kill methicillin and vancomycin-resistant bacteriaNo resistance from MRSAPotent activity against drug-resistant Gram-positive pathogens

Technology Application: Pharmaceuticals/biotech companiesAnimal medicineBacterial burden in skin wound infections

Detailed Technology Description: Herman SintimSintim Research GroupPurdue Chemistry

Countries: United States

Application No.: None

*Abstract: None

*Background: The discovery and development of antibiotics revolutionized health care in such a way that bacterial infections, which were otherwise deadly, could be treated; however, this was met with a rapid development of resistant bacterial strains that rendered many antibiotics ineffective. Consequently, millions of people are infected with drug-resistant bacterial strains yearly resulting in thousands of deaths. Efforts need to be directed towards identifying and developing novel structures as antibacterial agents with possibly novel mechanisms of action.

*IP Issue Date: None

*IP Type: Provisional

*Publications: Clement Opoku-Temeng et al., N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteriaEuropean Journal of Medicinal Chemistry, 2018https://doi.org/10.1016/j.ejmech.2018.06.023

*Stage of Development: Concept validated through theory, simulation, or models

*Web Links: Purdue Office of Technology CommercializationPurdue Innovation and EntrepreneurshipHerman SintimSintim Research GroupPurdue Chemistry

Country/Region: USA

For more information, please click Here